In The News Posted November 12, 2021 Share Posted November 12, 2021 TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- EC marketing authorization follows approvals in Japan, Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known...View the full article Quote Link to comment Share on other sites More sharing options...
Recommended Posts